The FDA approved a topical Janus kinase (JAK) inhibitor to treat a skin condition known as vitiligo. The new drug, known as ruxolitinib cream or by its brand name Opzelura, is the first and only ...

In this article, learn about the dosage, uses, and ongoing research underway for JAK inhibitors available in the United States, as well as common side effects, contraindications, and warnings.

Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

Panelists discuss how to select among the four available JAK inhibitors (Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib) based on patient-specific factors such as anemia, thrombocytopenia, and ...

Spotlight On > Myelofibrosis Myelofibrosis: Beyond Ruxolitinib — Other JAK inhibitors, combinations, and novel therapies offer more hope for patients. by Mike Bassett, Staff Writer, MedPage ...

Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the ...

Am I a good candidate for the topical JAK inhibitor ruxolitinib? Use this guide to start the conversation at your next doctor’s appointment. Download Now. Most Recent in Vitiligo.

Incyte INCY announced that the FDA has extended the review period for the supplemental new drug application (sNDA) for ...

But based on the results of previous work, Teijaro and his research team wondered whether a JAK inhibitor - like ruxolitinib - could increase T-cell production, while also improving checkpoint ...

HealthDay News — Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves signs of underlying myelofibrosis in JAK inhibitor-naive ...